Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
43
ATNM Quote, Financials, Valuation and Earnings
Last price:
$1.13
Seasonality move
:
15.01%
Day range:
$1.16 - $1.23
52-week range:
$1.02 - $2.41
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
384.75x
P/B ratio:
2.51x
Volume:
149.4K
Avg. volume:
109.2K
1-year change:
-1.74%
Market cap:
$34.6M
Revenue:
--
EPS (TTM):
-$1.11
Analysts' Opinion
-
Consensus RatingActinium Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $5.00, Actinium Pharmaceuticals, Inc. has an estimated upside of 350.45% from its current price of $1.18.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.00 representing 100% downside risk from its current price of $1.18.
Fair Value
-
According to the consensus of 4 analysts, Actinium Pharmaceuticals, Inc. has 350.45% upside to fair value with a price target of $5.00 per share.
ATNM vs. S&P 500
-
Over the past 5 trading days, Actinium Pharmaceuticals, Inc. has underperformed the S&P 500 by -7.99% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Actinium Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Actinium Pharmaceuticals, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Actinium Pharmaceuticals, Inc. reported revenues of $90K.
Earnings Growth
-
Actinium Pharmaceuticals, Inc. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Actinium Pharmaceuticals, Inc. reported earnings per share of -$0.16.
Enterprise value:
-17.6M
EV / Invested capital:
--
Price / LTM sales:
384.75x
EV / EBIT:
--
EV / Revenue:
-195.78x
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
0.70x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$729K
Return On Assets:
-49.88%
Net Income Margin (TTM):
-38443.33%
Return On Equity:
-133.63%
Return On Invested Capital:
-126.64%
Operating Margin:
-6324.44%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | $81K | $90K | -- | $90K | |
| Gross Profit | -$752K | -$725K | -$729K | -$202K | -$116K | |
| Operating Income | -$52.9M | -$45M | -$37.3M | -$12.6M | -$5.7M | |
| EBITDA | -$52.1M | -$44.2M | -$36.5M | -$12.4M | -$5.5M | |
| Diluted EPS | -$1.91 | -$1.40 | -$1.11 | -$0.37 | -$0.16 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $83.3M | $113.4M | $85.6M | $79.5M | $54.4M | |
| Total Assets | $84.5M | $116.8M | $88.9M | $82.1M | $56.2M | |
| Current Liabilities | $4.2M | $8.4M | $8.7M | $7.8M | $6.8M | |
| Total Liabilities | $4.2M | $45.6M | $45.4M | $43.9M | $42.4M | |
| Total Equity | $80.3M | $71.3M | $43.6M | $38.2M | $13.8M | |
| Total Debt | $88K | $2.2M | $1.7M | $1.2M | $544K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$47.6M | -$34.8M | -$25M | -$12M | -$6.3M | |
| Cash From Investing | -$169K | -$11K | -- | -- | -- | |
| Cash From Financing | $18.6M | $30.5M | -$217K | $4.6M | -$209K | |
| Free Cash Flow | -$47.8M | -$34.8M | -$25M | -$12M | -$6.3M | |
ATNM
Sector
Market Cap
$34.6M
$25.1M
Price % of 52-Week High
46.06%
48.72%
Dividend Yield
0%
0%
Shareholder Yield
0.29%
-1.6%
1-Year Price Total Return
-7.5%
-18.38%
Beta (5-Year)
-0.311
0.490
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.18
200-day SMA
Sell
Level
$1.48
Bollinger Bands (100)
Sell
Level
1.19 - 1.49
Chaikin Money Flow
Sell
Level
-29.9M
20-day SMA
Buy
Level
$1.13
Relative Strength Index (RSI14)
Buy
Level
50.21
ADX Line
Buy
Level
19.9
Williams %R
Neutral
Level
-62.7907
50-day SMA
Sell
Level
$1.23
MACD (12, 26)
Sell
Level
-0.01
25-day Aroon Oscillator
Buy
Level
44
On Balance Volume
Neutral
Level
34M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-7.0799)
Sell
CA Score
(Annual)
Level (-3.1553)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (3.768)
Sell
Piotroski F Score
(Annual)
Level (3)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. It also develops and markets medicines for relapsed or refractory cancer patients. The company was founded in 2000 and is headquartered in New York, NY.
Stock Forecast FAQ
In the current month, ATNM has received 3 Buy ratings 1 Hold ratings, and 0 Sell ratings. The ATNM average analyst price target in the past 3 months is $5.00.
-
Where Will Actinium Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Actinium Pharmaceuticals, Inc. share price will rise to $5.00 per share over the next 12 months.
-
What Do Analysts Say About Actinium Pharmaceuticals, Inc.?
Analysts are divided on their view about Actinium Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Actinium Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $2.00.
-
What Is Actinium Pharmaceuticals, Inc.'s Price Target?
The price target for Actinium Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $5.00 according to 4 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is ATNM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Actinium Pharmaceuticals, Inc. is a Buy. 3 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ATNM?
You can purchase shares of Actinium Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Actinium Pharmaceuticals, Inc. shares.
-
What Is The Actinium Pharmaceuticals, Inc. Share Price Today?
Actinium Pharmaceuticals, Inc. was last trading at $1.13 per share. This represents the most recent stock quote for Actinium Pharmaceuticals, Inc.. Yesterday, Actinium Pharmaceuticals, Inc. closed at $1.18 per share.
-
How To Buy Actinium Pharmaceuticals, Inc. Stock Online?
In order to purchase Actinium Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ATNM Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ATNM
Sector
P/E ratio
--
21.37x
PEG ratio
-0.02x
-0.01x
P/B ratio
2.51x
1.73x
Price / LTM sales
384.75x
1.46x
Growth Metrics
ATNM
Sector
Revenue growth
--
3.27%
Earnings growth
55.82%
12.13%
Revenue (5-year growth)
--
6.25%
Earnings forecast
-$0.19
-$0.20
Profitability
ATNM
Sector
Profitability FY 2024
-$811K
$2.3M
Return on invested capital
-126.64%
-33.43%
Return on assets
-49.88%
-29.94%
Return on equity
-133.63%
-40.07%
Earnings Date
Last Earnings Date
May
15
Next Earnings Date
Mar
14
Estimated Next Earnings Date
Jun
13
Balance Sheet
ATNM
Sector
Total cash
$53.4M
$24.9M
Short term investments
--
$23M
Total assets
$76.9M
$70.1M
Long term debt
$544K
$2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
92
APEI alert for Mar 13
American Public Education, Inc. [APEI] is up 26.24% over the past day.
Buy
52
PZZA alert for Mar 13
Papa John's International, Inc. [PZZA] is down 5.25% over the past day.
Buy
53
NBIS alert for Mar 13
Nebius Group NV [NBIS] is up 0.87% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
